X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SBI-100 is a cannabinoid receptor type 1 (“CB1”) agonist administered topically onto the eye. It is being evaluated for the treatment of primary open angle glaucoma & ocular hypertension.
Lead Product(s): Tetrahydrocannabinol Valine Hemisuccinate
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
Nimacimab is a negative-allosteric modulating antibody targeting the cannabinoid 1 receptor (CB1). Now it will undergo clinical development for the treatment of patients with obesity and chronic kidney disease.
Lead Product(s): Nimacimab
Therapeutic Area: Nutrition and Weight Loss Product Name: RYI-018
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
SBI-100 is a cannabinoid receptor type 1 (CB1) agonist administered topically onto the eye. It is being evaluated to lower intraocular pressure and in patients with primary open-angle glaucoma or ocular hypertension.
Lead Product(s): SBI-100
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
Through the acquisition, Skye expand its position as a leading endocannabinoid systemfocused pharmaceutical company by including, Bird Rock's lead asset, nimacimab, a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of CB1 signaling.
Lead Product(s): Nimacimab
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: RYI-018
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Bird Rock Bio
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 21, 2023
Details:
The net financing will be used to advance Phase 2 of SBI-100 OE, a first-in-class, topically-administered CB1 agonist focused on reducing intraocular pressure related to glaucoma and ocular hypertension.
Lead Product(s): SBI-100
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: 5AM Ventures
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 21, 2023
Details:
SBI-100 OE is a novel synthetically-derived molecule formulated as an eye-drop using a propriety nanoemulsion to improve delivery into the eye. It targets the CB1 receptor, which plays a key role in managing intraocular pressure associated with glaucoma.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
SBI-100 OE is a novel synthetically-derived molecule formulated as an eye-drop using a propriety nanoemulsion to improve delivery into the eye. It targets the CB1 receptor, which plays a key role in managing intraocular pressure associated with glaucoma.
Lead Product(s): SBI-100
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
SBI-100 (tetrahydrocannabinol) OE, a proprietary, synthetic cannabinoid derivative possessing a novel molecular structure and formulation that was rationally designed to enable better penetration of ocular tissue and effective topical delivery of a CB1R agonist.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
SBI-100 OE is prodrug of THC that increases solubility and polarity and, synthetic cannabinoid derivative possessing novel molecular structure and formulation was rationally designed to enable better penetration of ocular tissue and topical delivery of CB1R agonist.
Lead Product(s): SBI-100 OE
Therapeutic Area: Ophthalmology Product Name: SBI-100 OE
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
This outcome has already been shown in preclinical studies that have demonstrated notable advantages of Skye’s lead therapeutic drug, SBI-100 Ophthalmic Emulsion (Tetrahydrocannabinol), over the established clinical standard of care for treating glaucoma.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Ophthalmology Product Name: SBI-100
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emerald Health Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
